Exparel 266 MG per 20 ML Injection
- RxCUI
- 1191513
- RxNorm name
- Exparel 266 MG per 20 ML Injection
- Display name
- Exparel 266 MG per 20 ML Injection
- Full name
- Exparel 266 MG per 20 ML Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:18
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| EXPAREL | BUPIVACAINE | Pacira Pharmaceuticals, Inc. | bb5a9e59-0f51-11df-8a39-0800200c9a66 | 2025-12-12 | Warnings, Adverse reactions | 1191513 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| bb5a9e59-0f51-11df-8a39-0800200c9a66 | EXPAREL 1.3 % in 20 ML Injection [PSN] · 20 ML bupivacaine liposome 13.3 MG/ML Injection [Exparel] [SBD] · 20 ML Exparel 13.3 MG/ML Injection [SY] · Exparel 1.3 % in 20 ML Injection [SY] · Exparel 266 MG per 20 ML Injection [SY] | 5 | 32 | These highlights do not include all the information needed to use EXPAREL® safely and effectively. See full prescribing information for EXPAREL. EXPAREL (bupivacaine liposome injectable suspension), for infiltration or perineural use Initial U.S. Approval: 1972 | 20251212 |